NEXTBio Capital Management LP Purchases Shares of 615,720 Oric Pharmaceuticals, Inc. $ORIC

NEXTBio Capital Management LP purchased a new stake in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) during the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 615,720 shares of the company’s stock, valued at approximately $5,037,000. Oric Pharmaceuticals comprises 3.0% of NEXTBio Capital Management LP’s investment portfolio, making the stock its 14th biggest position. NEXTBio Capital Management LP owned about 0.63% of Oric Pharmaceuticals at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in ORIC. AQR Capital Management LLC acquired a new position in shares of Oric Pharmaceuticals in the 1st quarter valued at $276,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Oric Pharmaceuticals by 8.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,201 shares of the company’s stock valued at $226,000 after purchasing an additional 3,131 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Oric Pharmaceuticals by 9.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 294,784 shares of the company’s stock valued at $1,645,000 after purchasing an additional 24,778 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Oric Pharmaceuticals by 1,331.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 509,179 shares of the company’s stock valued at $2,841,000 after purchasing an additional 473,600 shares during the last quarter. Finally, Jane Street Group LLC boosted its holdings in shares of Oric Pharmaceuticals by 56.0% in the 1st quarter. Jane Street Group LLC now owns 31,198 shares of the company’s stock valued at $174,000 after purchasing an additional 11,198 shares during the last quarter. Institutional investors and hedge funds own 95.05% of the company’s stock.

Analysts Set New Price Targets

ORIC has been the topic of several recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Oric Pharmaceuticals in a report on Tuesday, April 21st. Citigroup reduced their target price on shares of Oric Pharmaceuticals from $17.00 to $16.00 and set a “buy” rating on the stock in a report on Tuesday, May 5th. The Goldman Sachs Group upgraded shares of Oric Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $15.00 target price on the stock in a report on Friday, May 15th. Stifel Nicolaus initiated coverage on shares of Oric Pharmaceuticals in a report on Friday. They set a “buy” rating and a $14.00 target price on the stock. Finally, Benchmark restated a “buy” rating on shares of Oric Pharmaceuticals in a report on Monday, June 8th. Fourteen research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $18.92.

Oric Pharmaceuticals Stock Performance

ORIC opened at $8.27 on Friday. The company has a 50-day moving average of $9.03 and a 200-day moving average of $10.17. The company has a market capitalization of $856.11 million, a P/E ratio of -5.74 and a beta of 1.04. Oric Pharmaceuticals, Inc. has a 1-year low of $7.23 and a 1-year high of $14.93.

Oric Pharmaceuticals (NASDAQ:ORIC) last released its earnings results on Monday, May 4th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.03). As a group, sell-side analysts expect that Oric Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Oric Pharmaceuticals Profile

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.